

# Philippe J Guerin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5271307/publications.pdf>

Version: 2024-02-01

178  
papers

12,815  
citations

47006

47  
h-index

27406

106  
g-index

182  
all docs

182  
docs citations

182  
times ranked

15356  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving anthelmintic treatment for schistosomiasis and soil-transmitted helminthiases through sharing and reuse of individual participant data. Wellcome Open Research, 2022, 7, 5.	1.8	5
2	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	2.3	1
3	Molecular surveillance for operationally relevant genetic polymorphisms in Plasmodium falciparum in Southern Chad, 2016–2017. Malaria Journal, 2022, 21, 83.	2.3	5
4	Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	2
5	Making data map-worthy—enhancing routine malaria data to support surveillance and mapping of Plasmodium falciparum anti-malarial resistance in a pre-elimination sub-Saharan African setting: a molecular and spatiotemporal epidemiology study. Malaria Journal, 2022, 21, .	2.3	0
6	Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015. International Journal of Infectious Diseases, 2022, 122, 612-621.	3.3	6
7	A Systematic Literature Review of Microscopy Methods Reported in Malaria Clinical Trials. American Journal of Tropical Medicine and Hygiene, 2021, 104, 836-841.	1.4	4
8	A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. PLoS Neglected Tropical Diseases, 2021, 15, e0009144.	3.0	34
9	Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009302.	3.0	12
10	Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009204.	3.0	11
11	Guidelines should not pool evidence from uncomplicated and severe COVID-19. Lancet, The, 2021, 397, 1262-1263.	13.7	11
12	Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices. BMC Medical Ethics, 2021, 22, 106.	2.4	29
13	WHO COVID-19 therapeutic guidelines – Authors' reply. Lancet, The, 2021, 398, 118.	13.7	2
14	The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform. PLoS Neglected Tropical Diseases, 2021, 15, e0009697.	3.0	13
15	Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans. PLoS Neglected Tropical Diseases, 2021, 15, e0009650.	3.0	8
16	Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform. PLoS Neglected Tropical Diseases, 2021, 15, e0009858.	3.0	2
17	Febrile illness mapping—much of the world without data and without evidence-based treatments. BMC Medicine, 2020, 18, 287.	5.5	4
18	Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Africa, 1980–2015. BMC Medicine, 2020, 18, 279.	5.5	31

#	ARTICLE	IF	CITATIONS
19	Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991â€“2019. <i>Malaria Journal</i> , 2020, 19, 374.	2.3	18
20	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. <i>Lancet, The</i> , 2020, 396, e53.	13.7	27
21	Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Southern Asia and South-eastern Asia, 1980â€“2015. <i>BMC Medicine</i> , 2020, 18, 299.	5.5	30
22	Towards harmonization of microscopy methods for malaria clinical research studies. <i>Malaria Journal</i> , 2020, 19, 324.	2.3	13
23	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 943-952.	9.1	25
24	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. <i>BMC Medicine</i> , 2020, 18, 138.	5.5	16
25	The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcr1 76T: a meta-analysis of individual patient data. <i>BMC Medicine</i> , 2020, 18, 47.	5.5	22
26	In emergencies, health research must go beyond public engagement toward a true partnership with those affected. <i>Nature Medicine</i> , 2020, 26, 308-309.	30.7	2
27	COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. <i>The Lancet Global Health</i> , 2020, 8, e754-e755.	6.3	128
28	The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?. <i>F1000Research</i> , 2020, 9, 225.	1.6	45
29	A living systematic review protocol for COVID-19 clinical trial registrations. <i>Wellcome Open Research</i> , 2020, 5, 60.	1.8	41
30	Baseline results of a living systematic review for COVID-19 clinical trial registrations. <i>Wellcome Open Research</i> , 2020, 5, 116.	1.8	26
31	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. <i>PLoS Medicine</i> , 2020, 17, e1003393.	8.4	32
32	The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of Plasmodium Treatment Efficacy Trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 359-368.	1.4	10
33	Title is missing!. , 2020, 17, e1003393.		0
34	Title is missing!. , 2020, 17, e1003393.		0
35	Title is missing!. , 2020, 17, e1003393.		0
36	Title is missing!. , 2020, 17, e1003393.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 17, e1003393.		0
38	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
39	Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand-Myanmar Border. Open Forum Infectious Diseases, 2019, 6, ofz264.	0.9	1
40	The effect of dose on the antimalarial efficacy of artesunate-mefloquine against Plasmodium falciparum malaria: a protocol for systematic review and individual patient data (IPD) meta-analysis. BMJ Open, 2019, 9, e027738.	1.9	4
41	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
42	Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. BMC Medicine, 2019, 17, 1.	5.5	465
43	Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. Clinical Pharmacology and Therapeutics, 2019, 106, 1299-1309.	4.7	27
44	Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study. BMC Medical Research Methodology, 2019, 19, 107.	3.1	5
45	Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Medicine, 2019, 17, 70.	5.5	55
46	Efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a protocol for systematic review and individual patient data (IPD) meta-analysis. BMJ Open, 2019, 9, e027503.	1.9	4
47	Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting. BMC Medical Research Methodology, 2019, 19, 215.	3.1	3
48	Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2019, 19, 91-101.	9.1	56
49	Malaria control in India: A national perspective in a regional and global fight to eliminate malaria. Journal of Vector Borne Diseases, 2019, 56, 41.	0.4	7
50	An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. Journal of Antimicrobial Chemotherapy, 2018, 73, 1737-1749.	3.0	47
51	Malaria and Nutritional Status Among Children With Severe Acute Malnutrition in Niger: A Prospective Cohort Study. Clinical Infectious Diseases, 2018, 67, 1027-1034.	5.8	24
52	Evaluating drug resistance in visceral leishmaniasis: the challenges. Parasitology, 2018, 145, 453-463.	1.5	51
53	The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Medicine, 2018, 16, 200.	5.5	106
54	Secondary analysis and participation of those at the data source. The Lancet Global Health, 2018, 6, e965.	6.3	46

#	ARTICLE	IF	CITATIONS
55	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1025-1034.	9.1	85
56	Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. <i>Malaria Journal</i> , 2018, 17, 75.	2.3	57
57	Molecular markers of resistance to amodiaquine plus sulfadoxine-pyrimethamine in an area with seasonal malaria chemoprevention in south central Niger. <i>Malaria Journal</i> , 2018, 17, 98.	2.3	32
58	Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 98.	4.1	149
59	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002579.	8.4	47
60	The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2017, 7, 181-190.	3.4	23
61	Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. <i>Malaria Journal</i> , 2017, 16, 430.	2.3	14
62	Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges. <i>Malaria Journal</i> , 2017, 16, 488.	2.3	21
63	Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review. <i>Malaria Journal</i> , 2017, 16, 491.	2.3	10
64	Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw229.	0.9	28
65	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. <i>PLoS Medicine</i> , 2017, 14, e1002212.	8.4	50
66	Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005781.	3.0	21
67	Systematic review of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiases and the case for data-sharing. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006053.	3.0	11
68	Precision global health in the digital age. <i>Swiss Medical Weekly</i> , 2017, 147, w14423.	1.6	53
69	Beyond open data: realising the health benefits of sharing data: Table 1. <i>BMJ</i> , The, 2016, 355, i5295.	6.0	51
70	The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD). <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004784.	3.0	15
71	Abundance of megalin and Dab2 is reduced in syncytiotrophoblast during placental malaria, which may contribute to low birth weight. <i>Scientific Reports</i> , 2016, 6, 24508.	3.3	11
72	Combating poor-quality anti-malarial medicines: a call to action. <i>Malaria Journal</i> , 2016, 15, 302.	2.3	41

#	ARTICLE	IF	CITATIONS
73	A link between poor quality antimalarials and malaria drug resistance?. Expert Review of Anti-Infective Therapy, 2016, 14, 531-533.	4.4	56
74	Ethical challenges in designing and conducting medicine quality surveys. Tropical Medicine and International Health, 2016, 21, 799-806.	2.3	14
75	Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia. Malaria Journal, 2016, 15, 452.	2.3	38
76	Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. BMC Medicine, 2016, 14, 167.	5.5	21
77	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
78	Avoiding Data Dumpsters – Toward Equitable and Useful Data Sharing. New England Journal of Medicine, 2016, 374, 2414-2415.	27.0	65
79	Understanding the mechanisms and drivers of antimicrobial resistance. Lancet, The, 2016, 387, 176-187.	13.7	1,633
80	Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. Malaria Journal, 2015, 14, 279.	2.3	46
81	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
82	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Medicine, 2015, 13, 212.	5.5	61
83	Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Medicine, 2015, 13, 305.	5.5	143
84	Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. BMJ: British Medical Journal, 2015, 350, h602.	2.3	17
85	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	9.1	363
86	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	5.5	37
87	Artemisinin resistance in Myanmar – Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 1002-1003.	9.1	0
88	The Largest Ebola Outbreak – What Have We Learned So Far. Journal of Medicine (Bangladesh), 2015, 16, 1-4.	0.2	3
89	Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
90	Artemisinin resistance – modelling the potential human and economic costs. Malaria Journal, 2014, 13, 452.	2.3	102

#	ARTICLE	IF	CITATIONS
91	International health research monitoring: exploring a scientific and a cooperative approach using participatory action research. <i>BMJ Open</i> , 2014, 4, e004104.	1.9	3
92	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 833-843.	1.4	204
93	Estimation of malaria haplotype and genotype frequencies: a statistical approach to overcome the challenge associated with multiclonal infections. <i>Malaria Journal</i> , 2014, 13, 102.	2.3	23
94	Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN). <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3889-3894.	3.2	25
95	Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database. <i>Malaria Journal</i> , 2014, 13, 139.	2.3	81
96	Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3033-3040.	3.0	22
97	Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum. <i>Malaria Journal</i> , 2013, 12, 249.	2.3	26
98	Made in Europe: will artemisinin resistance emerge in French Guiana?. <i>Malaria Journal</i> , 2013, 12, 152.	2.3	19
99	Impact of malaria during pregnancy on pregnancy outcomes in a Ugandan prospective cohort with intensive malaria screening and prompt treatment. <i>Malaria Journal</i> , 2013, 12, 139.	2.3	106
100	Early parasitological response following artemisinin-containing regimens: a critical review of the literature. <i>Malaria Journal</i> , 2013, 12, 125.	2.3	33
101	Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. <i>Malaria Journal</i> , 2013, 12, 35.	2.3	28
102	Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia. <i>Malaria Journal</i> , 2013, 12, 250.	2.3	42
103	Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. <i>Malaria Journal</i> , 2013, 12, 411.	2.3	28
104	Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. <i>Malaria Journal</i> , 2013, 12, 251.	2.3	30
105	Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5096-5103.	3.2	41
106	Trends in Antimalarial Drug Use in Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 857-865.	1.4	40
107	High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN) <i>In Vitro</i> Analysis and Reporting Tool. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3121-3130.	3.2	36
108	Infections in Children Admitted with Complicated Severe Acute Malnutrition in Niger. <i>PLoS ONE</i> , 2013, 8, e68699.	2.5	77

#	ARTICLE	IF	CITATIONS
109	Surveillance of Travellers: An Additional Tool for Tracking Antimalarial Drug Resistance in Endemic Countries. PLoS ONE, 2013, 8, e77775.	2.5	11
110	Performance of a Histidine-Rich Protein 2 Rapid Diagnostic Test, Paracheck PfA <sup>®</sup> , for Detection of Malaria Infections in Ugandan Pregnant Women. American Journal of Tropical Medicine and Hygiene, 2012, 86, 93-95.	1.4	24
111	Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infectious Diseases, The, 2012, 12, 888-896.	9.1	67
112	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malaria Journal, 2012, 11, 293.	2.3	38
113	Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malaria Journal, 2012, 11, 174.	2.3	28
114	Artemether-lumefantrine to treat malaria in pregnancy is associated with reduced placental haemozoin deposition compared to quinine in a randomized controlled trial. Malaria Journal, 2012, 11, 150.	2.3	17
115	Chloroquine-Resistant Malaria in Travelers Returning from Haiti after 2010 Earthquake. Emerging Infectious Diseases, 2012, 18, 1346-1349.	4.3	26
116	Evaluation of a Rapid Test for the Diagnosis of Cholera in the Absence of a Gold Standard. PLoS ONE, 2012, 7, e37360.	2.5	58
117	Mapping the Aetiology of Non-Malarial Febrile Illness in Southeast Asia through a Systematic Review—Terra Incognita Impairing Treatment Policies. PLoS ONE, 2012, 7, e44269.	2.5	106
118	The Threat of Artemisinin-Resistant Malaria. New England Journal of Medicine, 2011, 365, 1073-1075.	27.0	232
119	Performance of LED-Based Fluorescence Microscopy to Diagnose Tuberculosis in a Peripheral Health Centre in Nairobi. PLoS ONE, 2011, 6, e17214.	2.5	33
120	Avidity of Serogroup A Meningococcal IgG Antibodies after Immunization with Different Doses of a Tetravalent A/C/Y/W135 Polysaccharide Vaccine. Scandinavian Journal of Immunology, 2011, 74, 87-94.	2.7	6
121	Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malaria Journal, 2011, 10, 339.	2.3	236
122	Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malaria Journal, 2011, 10, 352.	2.3	111
123	Use of Filter Paper as a Transport Medium for Laboratory Diagnosis of Cholera under Field Conditions. Journal of Clinical Microbiology, 2011, 49, 3021-3023.	3.9	8
124	The Primacy of Public Health Considerations in Defining Poor Quality Medicines. PLoS Medicine, 2011, 8, e1001139.	8.4	90
125	Transmission of Plasmodium vivax in South-Western Uganda: Report of Three Cases in Pregnant Women. PLoS ONE, 2011, 6, e19801.	2.5	17
126	Evaluation of Combined LED-Fluorescence Microscopy and Bleach Sedimentation for Diagnosis of Tuberculosis at Peripheral Health Service Level. PLoS ONE, 2011, 6, e20175.	2.5	9



#	ARTICLE	IF	CITATIONS
127	Monitoring antimalarial resistance: launching a cooperative effort. <i>Trends in Parasitology</i> , 2010, 26, 221-224.	3.3	19
128	Meningitis Dipstick Rapid Test: Evaluating Diagnostic Performance during an Urban <i>Neisseria meningitidis</i> Serogroup A Outbreak, Burkina Faso, 2007. <i>PLoS ONE</i> , 2010, 5, e11086.	2.5	21
129	Reducing Wasting in Young Children With Preventive Supplementation: A Cohort Study in Niger. <i>Pediatrics</i> , 2010, 126, e442-e450.	2.1	31
130	Effectiveness of ready-to-use therapeutic food compared to a corn/soy-blend-based pre-mix for the treatment of childhood moderate acute malnutrition in Niger. <i>Journal of Tropical Pediatrics</i> , 2010, 56, 407-413.	1.5	70
131	Efficacy and safety of artemether+lumefantrine compared with quinine in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria: an open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 762-769.	9.1	96
132	Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). <i>Malaria Journal</i> , 2010, 9, 375.	2.3	27
133	Mortality Risk among Children Admitted in a Large-Scale Nutritional Program in Niger, 2006. <i>PLoS ONE</i> , 2009, 4, e4313.	2.5	26
134	Prevalence Study of Yaws in the Democratic Republic of Congo Using the Lot Quality Assurance Sampling Method. <i>PLoS ONE</i> , 2009, 4, e6338.	2.5	24
135	Field Evaluation of Two Rapid Diagnostic Tests for <i>Neisseria meningitidis</i> Serogroup A during the 2006 Outbreak in Niger. <i>PLoS ONE</i> , 2009, 4, e7326.	2.5	14
136	Outbreak of Hepatitis E Virus Infection in Darfur, Sudan: Effectiveness of Real-Time Reverse Transcription-PCR Analysis of Dried Blood Spots. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1931-1933.	3.9	15
137	Effect of Preventive Supplementation With Ready-to-Use Therapeutic Food on the Nutritional Status, Mortality, and Morbidity of Children Aged 6 to 60 Months in Niger. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 277.	7.4	99
138	Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e548.	3.0	65
139	No association between human herpesvirus 6 reactivation and cryptococcosis in human immunodeficiency virus-infected patients. <i>Journal of Medical Microbiology</i> , 2009, 58, 276-277.	1.8	0
140	Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of <i>falciparum</i> and <i>vivax</i> malaria. <i>Malaria Journal</i> , 2009, 8, 241.	2.3	69
141	Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 567-576.	9.1	65
142	Prevalence, Risk Factors, and Impact on Outcome of Cytomegalovirus Replication in Serum of Cambodian HIV-Infected Patients (2004-2007). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 486-491.	2.1	21
143	Global resistance surveillance: ensuring antimalarial efficacy in the future. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 593-600.	3.1	25
144	A Look Back at an Ongoing Problem: <i>Shigella dysenteriae</i> Type 1 Epidemics in Refugee Settings in Central Africa (1993-1995). <i>PLoS ONE</i> , 2009, 4, e4494.	2.5	31

#	ARTICLE	IF	CITATIONS
145	The dynamics of measles in sub-Saharan Africa. <i>Nature</i> , 2008, 451, 679-684.	27.8	305
146	Bleach Sedimentation: An Opportunity to Optimize Smear Microscopy for Tuberculosis Diagnosis in Settings of High Prevalence of HIV. <i>Clinical Infectious Diseases</i> , 2008, 46, 1710-1716.	5.8	42
147	Treatment of severe malnutrition with 2-day intramuscular ceftriaxone vs 5-day amoxicillin. <i>Annals of Tropical Paediatrics</i> , 2008, 28, 13-22.	1.0	20
148	Assessing Antimalarial Efficacy in a Time of Change to Artemisinin-Based Combination Therapies: The Role of MÃ©decins Sans FrontiÃ©res. <i>PLoS Medicine</i> , 2008, 5, e169.	8.4	14
149	Research in Complex Humanitarian Emergencies: The MÃ©decins Sans FrontiÃ©res/Epicentre Experience. <i>PLoS Medicine</i> , 2008, 5, e89.	8.4	31
150	Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e342.	3.0	16
151	Unacceptably High Mortality Related to Measles Epidemics in Niger, Nigeria, and Chad. <i>PLoS Medicine</i> , 2007, 4, e16.	8.4	105
152	Outbreak of Beriberi in a Prison in CÃ¢te D'Ivoire. <i>Food and Nutrition Bulletin</i> , 2007, 28, 283-290.	1.4	39
153	World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. <i>Malaria Journal</i> , 2007, 6, 119.	2.3	57
154	Meningitis Serogroup W135 Outbreak, Burkina Faso, 2002. <i>Emerging Infectious Diseases</i> , 2007, 13, 920-923.	4.3	46
155	Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. <i>Tropical Medicine and International Health</i> , 2007, 12, 274-283.	2.3	50
156	Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources. <i>BMC Public Health</i> , 2007, 7, 8.	2.9	14
157	CLONAL RECONQUEST OF ANTIBIOTIC-SUSCEPTIBLE SALMONELLA ENTERICA SEROTYPE TYPHI IN SON LA PROVINCE, VIETNAM. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 76, 1174-1181.	1.4	9
158	Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. <i>Lancet</i> , 2006, 367, 1335-1342.	13.7	411
159	Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. <i>Vaccine</i> , 2006, 24, 4890-4895.	3.8	58
160	Late vaccination reinforcement during a measles epidemic in Niamey, Niger (2003-2004). <i>Vaccine</i> , 2006, 24, 3984-3989.	3.8	20
161	Exploring the time to intervene with a reactive mass vaccination campaign in measles epidemics. <i>Epidemiology and Infection</i> , 2006, 134, 845-849.	2.1	34
162	Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?. <i>Tropical Medicine and International Health</i> , 2006, 11, 398-408.	2.3	60

#	ARTICLE	IF	CITATIONS
163	Pharyngeal carriage of <i>Neisseria meningitidis</i> in 19-year-old individuals in Uganda. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006, 100, 1159-1163.	1.8	16
164	Validation of single real-time TaqMan <sup>®</sup> PCR assay for the detection and quantitation of four major genotypes of hepatitis E virus in clinical specimens. <i>Journal of Medical Virology</i> , 2006, 78, 1076-1082.	5.0	55
165	High Mortality Associated with an Outbreak of Hepatitis E among Displaced Persons in Darfur, Sudan. <i>Clinical Infectious Diseases</i> , 2006, 42, 1679-1684.	5.8	173
166	A Large Outbreak of Hepatitis E among a Displaced Population in Darfur, Sudan, 2004: The Role of Water Treatment Methods. <i>Clinical Infectious Diseases</i> , 2006, 42, 1685-1691.	5.8	185
167	Effectiveness of Mass Oral Cholera Vaccination in Beira, Mozambique. <i>New England Journal of Medicine</i> , 2005, 352, 757-767.	27.0	258
168	Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. <i>Lancet, The</i> , 2005, 366, 308-313.	13.7	102
169	Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. <i>Lancet Infectious Diseases, The</i> , 2005, 5, 763-774.	9.1	194
170	Emergence of new <i>Salmonella</i> Enteritidis phage types in Europe? Surveillance of infections in returning travellers. <i>BMC Medicine</i> , 2004, 2, 32.	5.5	20
171	Gastro-enteritis outbreak among Nordic patients with psoriasis in a health centre in Gran Canaria, Spain: a cohort study. <i>BMC Infectious Diseases</i> , 2004, 4, 45.	2.9	7
172	Outbreak of <i>Salmonella</i> Livingstone infection in Norway and Sweden due to contaminated processed fish products. <i>Epidemiology and Infection</i> , 2004, 132, 889-895.	2.1	31
173	<i>Shigella dysenteriae</i> serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone. <i>Lancet, The</i> , 2003, 362, 705-706.	13.7	39
174	Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. <i>Lancet Infectious Diseases, The</i> , 2002, 2, 494-501.	9.1	678
175	Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. <i>Lancet Infectious Diseases, The</i> , 2002, 2, 564-573.	9.1	301
176	Precision global health: a roadmap for augmented action. <i>Journal of Public Health and Emergency</i> , 0, 4, 5-5.	4.4	5
177	The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.. <i>Wellcome Open Research</i> , 0, 7, 24.	1.8	5
178	Infectious diseases data observatory (IDDO) visceral leishmaniasis library of clinical therapeutic studies: A protocol for a living systematic review of clinical studies. <i>Wellcome Open Research</i> , 0, 7, 155.	1.8	3